You have joined the meeting as an attendee and will be muted throughout the meeting.

Good afternoon and welcome to MindMed Q2 2021 earnings call. This call engages [Indiscernible] Development for [Indiscernible] coordinating today's conference. I would like to draw your attention to the fact that this conference call contains forward-looking information, which may include but is not limited to statements, plans, strategies for MindMed. Forward-looking statements are made as of today's date and involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of MindMed to be materially different in the forward-looking statements. We draw your attention to the full disclaimer contained in our filings on SEDAR & Edgar Leading the call today will be interim MindMed CEO, Rob Barrow. Please email any questions you may have to investors@ MindMed.co. Rob, you may begin the call.

Thanks so much, Collin. And good afternoon and welcome to MindMed 's Q2 2021 Earnings call. As we continue our mission to discover, develop, and deploy psychedelic-inspired medicines and therapies to alleviate suffering and promote mental health. I'm Rob Barrow, and I'm CEO of MindMed. I'm also joined today by our Chief Financial Officer, Dave Guebert. Much has changed at MindMed over the past year and a half. However, our mission remains consistent. We will not waiver from our mission to discover, develop, and deploy innovative therapeutics through rigorous science and established regulatory pathways to address large problems in society, including opioid prices and mental health. We plan to further this mission by focusing on multiple generation psychedelic inspired therapies, including both classic psychedelic such as LSD, and novel psychedelic-inspired therapy such as our proprietary [Indiscernible] contract 18-MC. Given the potentially revolutionary nature of this new class of therapeutics, we also recognize the critical need to build additional tools to facilitate the adoption, access, and scalability of psychedelic therapy. To this end, we are advancing multiple projects through Albert, our digital medicine and technology division. During the second quarter of 2021, we remained keenly focused on the advancement of our core drug and digital development programs, as well as bolstering our pipeline with both internal and collaborative research development activities. Given the growth and advancements in our development, we also made great strides to continue building our internal infrastructure and attracting top talents from the pharmaceutical industry to lead our internal drug and digital development operations. In this regard, we were honored to add a new board member to our Board of Directors, Dr. Sarah Vinson, who is a triple Board-certified physician, specializing in adult, child, and adolescent forensic psychiatry. She's the founder of Lorio Site Group, a group mental…

Thanks, Rob. Our financial statements for the second quarter of 2021 were reviewed by RSM Canada LLP and have been approved by our audit committee and our Board of Directors. The complete financial statements, along with related management discussion and analysis, can be found in the system for electronic document analysis and retrieval, the electronic filing system for the disclosure of documents of issuers across Canada at www. sedar.com, and also on EDGAR at sec. gov/edgar. I will provide a brief summary of our quarter-end financial statements as a reminder; all figures are expressed in U.S. dollars. MindMed continues to build its operating capabilities and expand its clinical and research and development activities. The highlights of the quarter include the growth of our core team being assembled to execute our strategic plan. Our net and comprehensive loss for the 3 months ended June 30th, 2021, was $36.3 million, made up primarily of research and development costs of 4.7 million, general and administrative expenses of 6.6 million in non-cash items, specifically share-based compensation of 21.8 million, and amortization of intangible assets of 3.4 million. The increase in share-based compensation is primarily related to the transitioning of the CEO position. Research and development expenses for the quarter were comprised of payroll and consulting fees of 2.5 million, clinical research and regulatory cost of 924,000, manufacturing-related costs of 589,000, and other R&D costs of 657,000. Research and development expenditures include all direct and indirect costs of the programs, compensation, licensing fees or intellectual property, as well as manufacturing, clinical, and regulatory costs. General and administrative expenses for the quarter, consisted of payroll and consulting fees. Good. 0.6 million. Marketing and Investor Relations of 294,000, professional fees of 1.4 million, insurance of 645,000, public Company related costs of 408,000, and 1.1 million in other G&A. Turning to the balance sheet, our cash balance was 157 million, and our working capital was 147.8 million as of June 30th, 2021. Our cash used in operations was $11.5 million during the quarter. Net proceeds from the financing, preliminary option, and warrant exercises, was 7.9 million. With that, I'll turn the presentation back to Rob.

Thanks, Dave. That completes today's earnings call. Please follow-up with all questions to investors @mindmed.co. Thank you, everyone, for joining us and we look forward to being in touch with you all soon. End of Q&A :